Search results for "Pharmaceutical Science"

showing 10 items of 2702 documents

Prevention from radiation damage by natural products

2018

Abstract Background Radiotherapy is a mainstay of cancer treatment since decades. Ionizing radiation (IR) is used for destruction of cancer cells and shrinkage of tumors. However, the increase of radioresistance in cancer cells and radiation toxicity to normal tissues are severe concerns. The exposure to radiation generates intracellular reactive oxygen species (ROS), which leads to DNA damage by lipid peroxidation, removal of thiol groups from cellular and membrane proteins, strand breaks and base alterations. Hypothesis Plants have to deal with radiation-induced damage (UV-light of sun, other natural radiation sources). Therefore, it is worth speculating that radioprotective mechanisms ha…

0301 basic medicineCurcuminAntioxidantDNA damagemedicine.medical_treatmentPhytochemicalsPharmaceutical ScienceSilibininRadiation-Protective AgentsAscorbic AcidBiologyPharmacologyAntioxidantsLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsRadioresistanceStilbenesDrug DiscoverymedicineHumansRadiation InjuriesFlavonoidsPharmacologyRadiotherapyRadiochemistryPolyphenolsPlantsAscorbic acid030104 developmental biologyComplementary and alternative medicinechemistryResveratrol030220 oncology & carcinogenesisCancer cellCurcuminMolecular MedicineLipid PeroxidationReactive Oxygen SpeciesDNA DamagePhytomedicine
researchProduct

Curcumin downregulates expression of opioid-related nociceptin receptor gene (OPRL1) in isolated neuroglia cells.

2018

Abstract Background: Curcumin (CC) exerts polyvalent pharmacological actions and multi-target effects, including pain relief and anti-nociceptive activity. In combination with Boswellia serrata extract (BS), curcumin shows greater efficacy in knee osteoarthritis management, presumably due to synergistic interaction of the ingredients. Aim: To elucidate the molecular mechanisms underlying the analgesic activity of curcumin and its synergistic interaction with BS. Methods: We performed gene expression profiling by transcriptome-wide mRNA sequencing in human T98G neuroglia cells treated with CC (Curamed), BS, and the combination of CC and BS (CC-BS; Curamin), followed by interactive pathways a…

0301 basic medicineCurcuminmedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceDown-RegulationPharmacologyNociceptin Receptor03 medical and health sciencesOpioid receptorCell Line TumorDrug DiscoverymedicineHumansBoswelliaReceptorPharmacologyAnalgesicsChemistryPlant ExtractsGene expression profilingAnalgesics OpioidNociceptin receptor030104 developmental biologyMRNA SequencingComplementary and alternative medicineOpioidNeuropathic painReceptors OpioidMolecular MedicineADAMTS5 ProteinSignal transductionNeurogliamedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Bumetanide prevents brain trauma-induced depressive-like behavior

2019

AbstractBrain trauma triggers a cascade of deleterious events leading to enhanced incidence of drug resistant epilepsies, depression and cognitive dysfunctions. The underlying mechanisms leading to these alterations are poorly understood and treatment that attenuates those sequels not available. Using controlled-cortical impact (CCI) as experimental model of brain trauma in adult mouse we found a strong suppressive effect of the sodium-potassium-chloride importer (NKCC1) specific antagonist bumetanide on appearance of depression-like behavior. We demonstrate that this alteration in behavior is associated with a block of CCI-induced decrease in parvalbumin-positive interneurons and impairmen…

0301 basic medicineDOWN-REGULATIONpotassium chloride cotransporter 2 (KCC2)[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyHippocampusUP-REGULATION0302 clinical medicineMedicineCOTRANSPORTER KCC2NEURAL STEM-CELLBrain traumaDepression (differential diagnoses)Original Research0303 health sciencesNeurogenesisDepolarizationNeural stem cell3. Good healthADULT HIPPOCAMPAL NEUROGENESISneurogenesis[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologydepressionBumetanidemedicine.druginterneuron cell deathpsychiatric diseaseINHIBITIONbumetanidelcsh:RC321-571Cellular and Molecular Neuroscience03 medical and health sciencesINJURYlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMolecular Biology030304 developmental biologybusiness.industryMechanism (biology)GRANULE CELLSDentate gyrusAntagonist3112 Neurosciences[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology030104 developmental biologyDENTATE GYRUSDIURETIC BUMETANIDE[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologybusinessNeuroscience030217 neurology & neurosurgeryNeuroscience
researchProduct

Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators.

2016

Abstract The dopamine-amino acid conjugate DA-Phen was firstly designed to obtain a useful prodrug for the therapy of Parkinson's disease, but experimental evidence shows that it effectively interacts with D1 dopamine receptors (D1DRs), leading to an enhancement in cognitive flexibility and to the development of adaptive strategies in aversive mazes, together with a decrease in despair-like behavior. In this paper, homology modelling, molecular dynamics, and site mapping of D1 receptor were carried out with the aim of further performing docking studies on other dopamine conjugates compared with D1 agonists, in the attempt to identify new compounds with potential dopaminergic activity. Two n…

0301 basic medicineDopamineDopamine AgentsChemistry Techniques SyntheticPharmacology01 natural sciencesDocking03 medical and health sciencesDopamine receptor D1Drug StabilityDopamineCatalytic DomainDrug DiscoverymedicineAnimalsHumansAmino Acidschemistry.chemical_classificationConjugatePharmacologyPCA010405 organic chemistryChemistrySynthesiDrug Discovery3003 Pharmaceutical ScienceReceptors Dopamine D1DopaminergicOrganic ChemistryBrainGeneral MedicineProdrug0104 chemical sciencesAmino acidAmino acidRatsMolecular Docking Simulation030104 developmental biologyBiochemistryDocking (molecular)Dopamine receptorDrug DesignMolecular modellingConjugatemedicine.drugEuropean journal of medicinal chemistry
researchProduct

Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model

2017

The therapy of inflammatory bowel diseases is still rather inefficient, and about 80% of patients require surgery at some stage. Improving the treatments by more efficient medication is, therefore, an urgent medical need. The objective of this project was to demonstrate targeted delivery of Cyclosporine-A (CYA) to the inflamed areas of the intestinal mucosa after oral administration, enabling improved alleviation of the symptoms and, at the same time, reduced systemic drug absorption and associated adverse effects. As had already been demonstrated in previous studies, nano- to micrometer-sized drug particles will accumulate at inflamed mucosal areas, providing a platform for such purposes. …

0301 basic medicineDrugColonPolymersmedia_common.quotation_subjectAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyPharmacologyInflammatory bowel diseaseMice03 medical and health sciencesDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIntestinal mucosaOral administrationAnimalsMedicineLactic AcidIntestinal MucosaParticle SizeAdverse effectmedia_commonDrug CarriersMice Inbred BALB CCrohn's diseasebusiness.industryGeneral MedicineInflammatory Bowel Diseases021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityDisease Models Animal030104 developmental biologyCyclosporineNanoparticlesNanocarriers0210 nano-technologybusinessPolyglycolic AcidBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monocultu…

2017

The Caco-2 cellular monolayer is a widely accepted in vitro model to predict human permeability but suffering from several and critical limitations. Therefore, some alternative cell cultures to mimic the human intestinal epithelium, as closely as possible, have been developed to achieve more physiological conditions, as the Caco-2/HT29-MTX coculture and the triple Caco-2/HT29-MTX/Raji B models. In this work the permeability of 12 model drugs of different Biopharmaceutical Classification System (BCS) characteristics, in the coculture and triple coculture models was assessed. Additionally, the utility of both models to classify compounds according to the BCS criteria was scrutinized. The obta…

0301 basic medicineDrugColonmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyBiologydigestive systemPermeability03 medical and health sciencesCell Line TumorDrug DiscoverymedicineLow permeabilityHumansIntestinal Mucosamedia_commonHt29 mtxIntestinal permeability021001 nanoscience & nanotechnologymedicine.diseaseIntestinal epitheliumCoculture Techniques030104 developmental biologyIntestinal AbsorptionCaco-2Cell culturePermeability (electromagnetism)ImmunologyCancer researchMolecular MedicineCaco-2 Cells0210 nano-technologyHT29 CellsMolecular Pharmaceutics
researchProduct

Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

2015

Drug development in Systemic Lupus Erythematosus (SLE) has been hindered by poor translation from successful preclinical experiments to clinical efficacy. This lack of success has been attributed to the high heterogeneity of SLE patients and to the lack of understanding of disease physiopathology. Modelling approaches could be useful for supporting the identification of targets, biomarkers and patient subpopulations with differential response to drugs. However, the use of traditional quantitative models based on differential equations is not justifiable in a sparse data situation. Boolean networks models are less demanding on the required data to be implemented and can provide insights into…

0301 basic medicineDrugSystems biologymedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsDiseaseBioinformaticsAutoimmune Diseases03 medical and health sciencesmedicineAnimalsCluster AnalysisHumansLupus Erythematosus SystemicComputer Simulationmedia_commonAutoimmune diseaseLupus erythematosusbusiness.industrySystems Biologymedicine.diseaseTreatment Outcome030104 developmental biologyDrug developmentPharmacology ClinicalbusinessBiological networkSystems pharmacologyEuropean Journal of Pharmaceutical Sciences
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin

2015

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing ribavirin are reviewed. Ribavirin is highly soluble, but its permeability characteristics are not well defined. Therefore according to the Biopharmaceutical Classification System, and taking a “worst case” approach, ribavirin should be assigned to class III. As ribavirin is transported across the brush border membrane of the human jejunum by hCNT2, it shows saturable uptake in the intestine. However, no common excipients have been shown to compete for ribavirin absorption, nor have problems with BE of immediate release rib…

0301 basic medicineDrugribavirinDrug Compoundingvirusesmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceCapsulesPharmacologyBioequivalenceAntiviral Agents030226 pharmacology & pharmacyPermeabilityArticleDosage formExcipients03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTherapeutic indexHumansMedicineImmediate releasemedia_commonbusiness.industrysolubilityRibavirinvirus diseasesbiochemical phenomena metabolism and nutritionBCSbiowaiver030112 virologydigestive system diseasesBiopharmaceuticalTherapeutic EquivalencychemistryManufacturing methodsbusinessabsorptionTabletsJournal of Pharmaceutical Sciences
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct